1 / 20

Digoxin toxicity

Digoxin toxicity. Alex Battistini. Overview. 1. 2. Pharmacology of digoxin. Clinical Uses. Introduction. Toxicity and management. 3. 4. Introduction. Digitalis: Cardiac glycoside that occurs naturally in plants

clark
Download Presentation

Digoxin toxicity

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Digoxin toxicity Alex Battistini

  2. Overview 1 2 Pharmacology of digoxin Clinical Uses Introduction Toxicity and management 3 4

  3. Introduction • Digitalis: Cardiac glycoside that occurs naturally in plants • Its medical use dates back from the 18th century (usage of foxglove) to treat dropsy (oedematous state) • In the 19th century digitalis strengthened the pulse when weak and slowed in down when it was strong… • Nowadays digoxin is the only one available in the market. Digoxin Digitoxin Ouabain

  4. Pharmacology of digoxin Structure-activity relationships • Steroid cyclopentenophenanthrene nucleus • Glycone + aglycone portions • Aglycone portion is pharmacologically active • Glycone portion anchors to the muscle cell membrane

  5. Pharmacology of digoxin Mechanism of action • Binds to the α-subunit of the Na+-K+-ATPase pump (competitive reversible inhibition) • IC Na+  inhibits Ca+2 efflux by the Na+-Ca+2 exchanger • IC Ca+2  increased myocardial contractility (positive inotropic effect)

  6. Haemodynamic effects • In the failing heart it improves LVEF, PCWP, CO (increased renal perfusion and mobilisation of oedema) • Varies according to the LV function • In normal subjects it increases contractility but also causes a reflex SVR (no change in cardiac output)

  7. Other effects NEUROHORMONAL • Modulates maladaptive neuroendocrine activation (noradrenaline, renin and aldosterone) • PNS tone and inhibits SNS activity • Improves carotid baroreceptor sensitivity (dampened in HF) ELECTROPHYSIOLOGICAL • Closely related to effects on ANS • PNS + SNS = automaticity + AV conduction (aka slow heart rate) • Prolonged PR, short QTc,

  8. Clinical Uses Symptomatic CHF

  9. Clinical Uses Rate-control for persistent and permanent AF

  10. Digoxin toxicity • Incidence has decreased due to alternative CVS drugs and improved serum drug concentration monitoring • In the 70s: 20% of digitalised patients, mortality up to 40%. • In the 90s: DIG trial showed 2% toxicity in inpatients • Predisposing conditions: • Aging • Kidney disease • Drug interactions

  11. Drug interactions

  12. Digoxin Toxicity • Signs and symptoms

  13. Digoxin toxicity • Diagnosis • High level of suspicion • Signs & Symptoms are non-specific • Anorexia, N&V are early signs of toxicity • ECG changes are very variable • Overall increased automaticity of all cardiac cells except SA node • VF is commonest cause of death in digoxin toxicity • Serum level concentrations: • <0.5ng/mL likely non-toxic • 0.5 – 1.0ng/mL optimal (DIG trial) • >2ng/mL usually associated with toxicity • NB: Relationship between plasma concentrations and observed pharmacological effects is not always consistent

  14. Digoxin toxicity

  15. Treatment • Supportive care (ABCDE) • Correction of predisposing causes • Hypokalaemia and hypomagnesaemia require replacement with careful monitoring (supplemental K+ decreases binding of digoxin to cardiac myocytes) • Hyperkalaemia(K+ > 5.0mmol/L) in the setting of digoxin toxicity has a high mortality rate and needs correction • Calcium is contraindicated • Hypoxaemia • Antiarrhythmic drugs • Phenytoin: 0.5 – 1.5mg/kg • Lignocaine: 1 – 2mg/kg • Atropine: 35 – 70mcg/kg

  16. Life-threatening digitalis toxicity • Digoxin binding therapy • Fab fragments (e.gDigibind injections) • Binds to digoxin, making it unavaliable to interact with the Na+-K+-ATPase pump • The Fab-Digoxin complex gets excreted unchanged in urine • Digoxin from peripheral tissues then gets redistributed to blood to maintain equilibrium, reducing digoxin concentration. • 80 – 90% effectiveness in reversing symptoms of toxicity with complete reversal within 4 hours

  17. Life-threatening digoxin toxicity • Indications for Fab fragments • Severe ventricular arrhythmias (e.g. VT or VF) • Progressive bradyarrhythmias (e.g. severe sinus bradycardia or 2nd or complete heart block) not responsive to atropine • Cardiac arrest • Digitalis-induced progressive elevation of serum K+ > 5mmol/L • Ingestion of more than 10mg (adults) or 4mg (children) or ingestions causing SDC > 10ng/mL

  18. Life-threatening digoxin toxicity • Dosage of Fab fragments

  19. References • The Digitalis Investigation Group (DIG). The effect of digoxin on mortality and morbidity in patients with heart failure. N Eng J Med 1997; 336:525-33 • National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Guidelines for the prevention, detection and management of chronic heart failure in Australia. Updated July 2011. www.csanz.edu.au • NICE Guidelines (UK): Atrial Fibrillation: The Management of Atrial Fibrillation. June 2006. www.guidance.nice.org.uk • Rey P. Vivo et al: Digoxin: Current Use and Approach to Toxicity. The Am J Med Sci2008; 336: 423-428 • Manyank K Mittal et al: Contemporary Indications and Therapeutic Implications for Digoxin Use. Am J Therap 2011; 18(4): 280-287 • Michael Ehle et al: Digoxin: Clinical Highlights: A Review of Digoxin and Its Use in Contemporary Medicine. Crit Path Cardio 2011; 10(2): 93-98 • MIMS Online

  20. THANK YOU

More Related